Table I.

All human sera tested contain anti-Neu5Gc Igs

Serum no.Neu5Gc-specific Aba (μg/ml ± SD)b
IgGIgAIgM
13.48 ± 0.070.06 ± 0.010.38 ± 0.03
20.19 ± 0.030.16 ± 0.011.03 ± 0.11
30.39 ± 0.030.18 ± 0.040.57 ± 0.16
41.94 ± 0.150.28 ± 0.020.42 ± 0.03
50.31 ± 0.050.11 ± 0.030.33 ± 0.15
63.35 ± 0.052.97 ± 0.140.70 ± 0.18
72.37 ± 0.090.46 ± 0.050.28 ± 0.15
85.42 ± 0.130.08 ± 0.050.59 ± 0.03
93.18 ± 0.080.68 ± 0.030.79 ± 0.08
103.48 ± 0.070.06 ± 0.000.38 ± 0.09
110.98 ± 0.050.24 ± 0.020.46 ± 0.03
122.08 ± 0.070.11 ± 0.020.37 ± 0.02
130.25 ± 0.050.03 ± 0.010.17 ± 0.06
146.35 ± 0.250.35 ± 0.040.66 ± 0.05
150.09 ± 0.030.13 ± 0.020.26 ± 0.01
160.54 ± 0.090.32 ± 0.070.38 ± 0.00
170.84 ± 0.050.16 ± 0.030.26 ± 0.01
180.42 ± 0.070.17 ± 0.020.18 ± 0.02
190.29 ± 0.050.11 ± 0.030.31 ± 0.06
201.16 ± 0.070.19 ± 0.030.14 ± 0.03
210.67 ± 0.030.09 ± 0.010.21 ± 0.03
  • a Neu5Gc-specific Ab in serum were quantified as described in Materials and Methods.

  • b SD was determined from triplicate wells.